Non-small cell lung cancer
Conditions
Interventions
treated by S-1 and cisplatin with concurrent carbon-ion radiotherapy
Sponsors
Ohno Tatsuya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically and/or cytologically proven unresectable non-small cell lung cancer of which stage is IIIA, IIIB, or IIIC 2. More than 20 years old, and less than 75 years old 3. ECOG Performace Status (PS) 0-1 4. The case at least more than three months survival is expected 5. The case having a measurable lesion 6. Meets the following criteria absolute neutrophil >=1500/mm3 platelet count >=100,000/mm3 hemoglobin >=9.0 g/dL AST and ALT = 60ml/min SpO2 >=90 percent 7.Written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: 1. Interstitial pneumonia , fibroid lung confirmed by CT. 2. Anti-side hilar lymph nodes metastasis, atelectasis, pleural effusion, abdominal dropsy, pericardial fluid which need drainage 3. Patient with active double cancer. 4. Patient with serious disease condition (uncontrollable angina cordis, cardiac infarction or heart failure within 3 months, uncontrollable hypertension, diabetes mellitus, etc) 5. Pregnancy 6. History of cisplatin or other platinum allergy 7. History of S-1 allergy 8. Patient with tumor invasion to heart, great vessels, trachea, esophagus, tracheal bifurcation or ipsilateral lung metastasis 9. Patient with active HBV or HCV or HIV infection 10. Patient with concurrent treatment including chemotherapy, immunotherapy, biological drug, and hormone treatment 11. Considered as unfit by attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| determine recommanded dose of S-1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Response rate, Progression free survival , Overall Survival | — |
Contacts
Public ContactYosuke Miura
Gunma University Hospital
Outcome results
None listed